Peter McNamara
About Peter McNamara
Peter McNamara, Ph.D., age 54, is Chief Scientific Officer (CSO) of Tectonic Therapeutic (TECX), serving in this role since June 2022 after joining as SVP, Head of Research in June 2021 . He previously led biotherapeutics and biotechnology at the Genomics Institute of the Novartis Research Foundation (NIBR, San Diego) and served on its executive committee and strategy council managing ~50 preclinical and early clinical programs; across his career he played a critical role in over 10 INDs, two of which are now approved . Dr. McNamara holds a Ph.D. and B.S. in Biochemistry from the National University of Ireland, Galway . Company-level pay-versus-performance disclosures show cumulative TSR value of a fixed $100 investment at $190.77 (2023) and $539.70 (2024), while net losses were $42.8M (2023) and $58.0M (2024) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Tectonic Therapeutic, Inc. | Chief Scientific Officer | Jun 2022–present | Leads R&D; career record includes >10 INDs and 2 approvals |
| Tectonic Therapeutic, Inc. | SVP, Head of Research | Jun 2021–Jun 2022 | Built/led research function |
| Novartis (Genomics Institute of the Novartis Research Foundation, San Diego) | Executive Director, Biotherapeutics & Biotechnology | Jun 2018–Apr 2021 | Exec committee/strategy council; managed ~50 preclinical/early clinical programs |
| Novartis (GNF) | Various positions | 2005–Jun 2018 | Leadership roles in biotherapeutics/biotech |
| Phenomix Corporation | Director of Pharmacology | Not disclosed | Therapeutic area leadership |
| University of Pennsylvania (Institute for Translational Medicine & Therapeutics) | Faculty | Not disclosed | Academic translational research |
External Roles
No public company board or external directorships for McNamara are disclosed in the proxy .
Fixed Compensation
Not disclosed for McNamara (he was not a Named Executive Officer in FY2024) .
Performance Compensation
The company operates an annual incentive program with targets set by the Board/Compensation Committee; 2024 targets disclosed for CEO/CFO/CMO only (not for CSO) at 55%, 40%, and 40% of base salary, respectively . No performance metric weightings, targets, or payouts are disclosed for McNamara specifically .
Equity Ownership & Alignment
Insider Transactions and Holdings
| Date | Transaction | Shares/Units | Price ($) | Post-transaction holdings | Notes |
|---|---|---|---|---|---|
| 06/20/2024 | Merger exchange of legacy holdings | — | — | — | Legacy Tectonic shares and options converted into TECX per 0.534419990 exchange ratio after reverse split; legacy options assumed on same terms adjusted for ratio |
| 12/03/2024 | Option exercise (Code M) | 3,500 | 2.38 | 14,188 common shares direct; 34,459 derivative (options) outstanding | Vesting footnotes reflect legacy option schedule; filing lists holdings after exercise |
| 09/25/2025 | RSU grant | 4,550 | — | 33,879 common shares direct after grant | RSUs vest in three equal annual installments on 9/25/2026, 9/25/2027, and 9/25/2028 |
| 09/25/2025 | Employee stock option grant | 8,260 | 14.71 | 8,260 options outstanding | Vests monthly over 48 months beginning 10/25/2025; expires 9/24/2035 |
- We did not observe open‑market sales in the reviewed filings; activity consisted of the June 2024 merger exchange, a December 2024 option exercise, and September 2025 grants .
Equity Awards and Vesting
| Grant Date | Award Type | Shares/Units | Strike ($) | Vesting | Expiration |
|---|---|---|---|---|---|
| 09/25/2025 | RSUs | 4,550 | — | 3 equal annual installments on 09/25/2026, 09/25/2027, 09/25/2028 | — |
| 09/25/2025 | Stock Option | 8,260 | 14.71 | Monthly over 48 months beginning 10/25/2025 | 09/24/2035 |
Hedging, Pledging, and Trading Controls
- The company prohibits directors/officers from hedging, derivatives, options trading (other than compensatory awards), exchange funds, and pledging or holding in margin accounts . An Insider Trading Policy governs trading and is filed as an exhibit to the 2024 10‑K .
Clawbacks
- Incentive compensation recoupment policy applies to executive officers for the last 3 completed fiscal years in the event of a restatement due to material non‑compliance with financial reporting requirements .
Employment Terms
| Item | Detail |
|---|---|
| Employment start at Tectonic | Joined June 2021 as SVP, Head of Research; promoted to CSO June 2022 |
| Contract term/expiration | Not disclosed for McNamara in the proxy |
| Severance/change‑in‑control | Severance Plan benefits detailed for Named Executive Officers; participation for CSO not specifically disclosed |
| Non‑compete / non‑solicit | Not disclosed for McNamara |
Investment Implications
- Alignment: Multi‑year, time‑based vesting on RSUs (annual tranches through 2028) and options (monthly vesting over 48 months starting October 2025) promotes retention and aligns upside with long‑term value creation; no performance‑conditioned equity for the CSO was disclosed .
- Insider selling pressure: Monitor 10b5‑1/blackout windows and scheduled vest dates (annual RSU vesting each September 25 and monthly option vesting starting October 25, 2025) as potential supply catalysts; reviewed filings show grants/exercise, not open‑market sales .
- Governance risk mitigants: Robust prohibitions on hedging/pledging and an SEC‑aligned clawback policy reduce misalignment and restatement‑related risk .
- Execution track record: McNamara’s history managing ~50 programs and advancing >10 INDs (with 2 approvals) is supportive of R&D execution; continued company‑level net losses and biotech development risk warrant scrutiny of capital runway and program milestones when assessing pay‑for‑performance linkage .